The ability to selectively deliver payloads (such as radionuclides, cytostatics, or siRNA) into the cytoplasm of tumor cells is perhaps the most important difference to another popular theranostic target, fibroblast activation protein (FAP) [22, 23]. The gene discussed is FAP; the disease is neoplasm.